Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur
About OASIS 4 OASIS 4 was a 64-week phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with one or more weight-related comorbidities.1 People with diabetes were excluded.1 OASIS 4 included a 64-week treatment period, including a 12-week dose escalation, and a 7-week off-treatment follow-up period. In total, 307 participants were randomized in a 2:1 ratio to once-daily oral semaglutide 25 mg or placebo, alongside lifestyle intervention for 64 weeks.1 For those taking Wegovy® pill, 76% achieved 5% or greater body weight loss (from a baseline body weight of 235 lb.) versus 31% taking placebo (from a baseline body weight of 231 lb.).1
About OASIS 4 OASIS 4 was a 64-week phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with one or more weight-related comorbidities.1 People with diabetes were excluded.1 OASIS 4 included a 64-week treatment period, including a 12-week dose escalation, and a 7-week off-treatment follow-up period. In total, 307 participants were randomized in a 2:1 ratio to once-daily oral semaglutide 25 mg or placebo, alongside lifestyle intervention for 64 weeks.1 For those taking Wegovy® pill, 76% achieved 5% or greater body weight loss (from a baseline body weight of 235 lb.) versus 31% taking placebo (from a baseline body weight of 231 lb.).1
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | Novo Nordisk nach Split | ||
| 2 | Novo Nordisk |
|
|
Thema | ||
|---|---|---|---|
| 1 | Dax Prognose | +1,84 % | |
| 2 | DAX Hauptdiskussion | +1,84 % | |
| 3 | RHEINMETALL Hauptdiskussion | +4,15 % | |
| 4 | IPO CSG | -6,76 % | |
| 5 | EUROPEAN LITHIUM Hauptdiskussion | -0,20 % | |
| 6 | Strategy B | -4,37 % | |
| 7 | für alle, die es ehrlich meinen beim Traden. | ||
| 8 | INTEL Hauptdiskussion | +4,61 % | |
| 9 | Diginex nach RS - sachliche Diskussion | -2,31 % | |
| 10 | AFC ENERGY Hauptdiskussion | +0,57 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | RHEINMETALL Hauptdiskussion | +4,13 % | |
| 2 | IPO CSG | -6,54 % | |
| 3 | Strategy B | -4,60 % | |
| 4 | EUROPEAN LITHIUM Hauptdiskussion | -0,20 % | |
| 5 | Battalion | -2,88 % | |
| 6 | INTEL Hauptdiskussion | +5,73 % | |
| 7 | AFC ENERGY Hauptdiskussion | +0,57 % | |
| 8 | Diginex nach RS - sachliche Diskussion | -2,31 % | |
| 9 | Hims & Hers Health Registered (A) Hauptdiskussion | -4,81 % | |
| 10 | NVIDIA Hauptdiskussion | +1,93 % | Alle Diskussionen |